Rubedo Life Sciences is capable of European expansion in the field of the first clinical studies

• Phase 1-Dermatology-Studie des Hauptkansen RLS-1496 soll Anfang 2025 in Europe begins

• Europäischer Hauptsitz und clinicalr Betrieb in Mailand, Italy, eingerichtet

• CDP Venture Capital has Rubedos in Series A along with other new investors

SUNNYVALE, California, October 24, 2024–(BUSINESS WIRE)–Rubedo Life Sciences, a biopharmaceutical company, has developed first-in-class therapeutic therapies that treat the changing illness, heal the disease, open the door to European homes and clinical care in Thailand. That happened in the past of the first phase 1 study of the Unternehmens for RLS-1496, a First-in-Class-Therapy for entzündliche Hauterkrankungen, which will be continued for a few more years in Europe. While the first clinical study of internal medicine is taking place, the other half of the headquarters in Kaliforni during the course of time is a study of the global analysis, the alternative ranking on the lives of the patients.

‘With the best medicine in a clinical phase it is exciting, talented talent and the infrastructure on the continent are useful, a rapid treatment in the field of the treatment method in first-line therapy for patients with high blood pressure, at the seneszente Zellen eine Rolle spielen, and for the future development,” says Marco Quarta, CEO and Mitgründer of Rubedo Life Sciences. “With the support of high-quality EU investors, who are happy with CDP Venture Capital, this Expansion in Europe cannot be achieved, so we will continue to do so globales Unternehmen become.”

“We are partners and partners and the expansion of Rubedo Life Sciences in Italy reflects the two most important priorities of the countries for the wider future: strategic investments in AI and biotechnology and the development of talented talents. Die Investition reflects our commitment to the broader innovation innovation and the sharper vision of Italy’s position as a company for these hochwirksamen industries,” says Agostino Scornajenchi, CEO and Geschäftsführer of CDP Venture Capital.

RLS-1496 is a current wide-ranging therapeutic subject, and the phase 1 research world of patients with higher insanity, one of the Sicherheit in the first endpoints to test. The secondary endpoint is an important factor and a strong biomarker. RLS-1496 could be used as a topical treatment, an effective treatment in the form of a systemic broadened therapy for its occurrence.

Read on